Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 8.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 204,604 shares of the company's stock after selling 18,121 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.09% of Hims & Hers Health worth $4,947,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in HIMS. Janus Henderson Group PLC raised its stake in Hims & Hers Health by 17.3% during the 4th quarter. Janus Henderson Group PLC now owns 80,069 shares of the company's stock valued at $1,936,000 after acquiring an additional 11,800 shares during the last quarter. Jasper Ridge Partners L.P. raised its stake in shares of Hims & Hers Health by 3.6% during the fourth quarter. Jasper Ridge Partners L.P. now owns 110,825 shares of the company's stock worth $2,680,000 after purchasing an additional 3,812 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $4,900,000. Gotham Asset Management LLC purchased a new position in Hims & Hers Health in the 4th quarter valued at $440,000. Finally, Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HIMS shares. Bank of America lifted their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their target price for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Citigroup restated a "sell" rating and set a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Trading Down 1.8%

Shares of NYSE HIMS traded down $1.13 during midday trading on Tuesday, reaching $61.21. 35,648,545 shares of the stock were exchanged, compared to its average volume of 19,528,885. The stock has a 50 day moving average price of $36.01 and a 200-day moving average price of $34.19. The company has a market capitalization of $13.70 billion, a P/E ratio of 139.12 and a beta of 1.84. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the transaction, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. The trade was a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the sale, the chief executive officer now owns 173,655 shares in the company, valued at $5,900,796.90. This represents a 42.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 618,936 shares of company stock worth $25,182,692 in the last ninety days. Insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.